Unknown OBSERVATIONAL NCT00899262

Biomarkers for Early Detection of Lung Cancer in Patients With Lung Cancer, Participants at High-Risk for Developing Lung Cancer, or Healthy Volunteers

Early Detection of Lung Cancer: Metabolic Biomarkers for High Risk Screening (MEDLUNG)

Sponsor: South West Wales Cancer Institute

Conditions Lung Cancer Tobacco Use Disorder

Interventions Fourier transform infrared spectroscopy diagnostic bronchoscopy immunohistochemistry staining method laboratory biomarker analysis sputum cytology

Updated 6 times since 2017 Last updated: Aug 23, 2013 Started: Apr 30, 2008 Primary completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Lung Cancer and Tobacco Use Disorder and is currently ongoing. South West Wales Cancer Institute leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Apr 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

South West Wales Cancer Institute

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Llanelli, United Kingdom
• Swansea, United Kingdom